Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2019 09:36 ET | Source: Mark A. Tepper, P.A.

UBS and former UBS Broker William Hobby put Claimants in Harm’s Way - Customer Claim filed by Mark Tepper law firm alleges

FT. LAUDERDALE, Fla., April 08, 2019 (GLOBE NEWSWIRE) -- The law firm of Securities Fraud Attorney Mark A. Tepper has filed claim against UBS [NYSE: UBS] on behalf of a Georgia couple who entrusted...
June 02, 2017 07:15 ET | Source: Cempra, Inc.

Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

CHAPEL HILL, N.C., June 02, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
April 28, 2017 07:00 ET | Source: Cempra, Inc.

Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update

CHAPEL HILL, N.C., April 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
March 13, 2017 07:00 ET | Source: Cempra, Inc.

Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options

CHAPEL HILL, N.C., March 13, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and...
March 03, 2017 07:00 ET | Source: Cempra, Inc.

Cempra to Present at 29th Annual ROTH Conference

CHAPEL HILL, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and...
February 28, 2017 06:45 ET | Source: Cempra, Inc.

Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results

—Management to host webcast and conference call today at 8:45 a.m. ET— CHAPEL HILL, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company...
February 24, 2017 07:00 ET | Source: Cempra, Inc.

Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI

—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...
February 14, 2017 16:15 ET | Source: Cempra, Inc.

Cempra to Report Fourth Quarter and Full Year 2016 Financial Results

CHAPEL HILL, N.C., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
February 08, 2017 09:41 ET | Source: Cempra, Inc.

CORRECTING and REPLACING -- Cempra to Present at Upcoming Investor Conferences

CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cempra, Inc. (Nasdaq:CEMP), the Leerink Partners conference should be noted...
February 08, 2017 07:30 ET | Source: Cempra, Inc.

Cempra to Present at Upcoming Investor Conferences

CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

Next Page keyboard_arrow_right